Daniella Kranjac

Our mission is to fast-track therapeutics development with improved properties and performance. We are revolutionizing the design of next-generation drug products by leveraging active machine learning, advanced robotics and deep pharmaceutical expertise. Our unique closed-loop technology helps us deliver innovation in every molecule we touch.

Vernal Biosciences is a CDMO democratizing the use of mRNA through a quality-first approach to manufacturing mRNA for all purposes.

Founded in 2018, Seattle-based Alpenglow Biosciences is a privately held, early-stage life sciences company focused on accelerating drug development and improving clinical diagnostics with AI-enabled, 3D imaging technology. Our platform solution provides new spatial biology insights with greater accuracy by digitizing entire tissues while keeping samples intact for additional analysis. Alpenglow partners with pharmaceutical companies to develop better therapeutics and greater understanding of biodistribution, mechanism of action, and rank ordering of potential candidates using our patented technology. Five of the top 10 pharma companies work with Alpenglow to accelerate development timelines, gain new insights, and improve therapeutic success. We are hiring talented individuals for roles in business development, wet lab, hardware, and software.

"Human Data for Next Generation Medicines" Curi Bio unlocks novel workflows and critical human data to inform R&D decision-making. Through an integrated platform featuring advanced 3D tissue models of disease, biosystems enabling clinically relevant functional analyses, and AI/ML-enabled insights, Curi Bio merges functional and analytical assessments for drug safety, efficacy, and potency

CellFE is a cell engineering startup that enables development and manufacturing of the new generation of medicines – cell therapies. CellFE has developed a unique microfluidic platform to solve one of the most pressing issues of therapeutic cell engineering –efficiently delivering gene-editing molecules into cells while preserving cell viability. CellFE’s technology: • Enables development of previously inaccessible cell therapies by providing means for transporting hard-to-deliver molecules into the cells. • Accelerates commercialization of existing cell therapies by significantly reducing cost, complexity, and processing time, while improving the efficacy and safety of the cell engineering process.

Xcell Biosciences (xcellbio) is a San Francisco-based life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing. Xcell’s mission is to democratize maintenance, expansion and control of any primary cell type through its bench-top primary cell control systems, reagent kits, software, and standardized protocols. The technology delivers simple control of primary cell types from blood or solid tissue, including a range of immune cells, stem cells, and tumor cells. This patient-centric technology offers a unique and proprietary capability to improve immunotherapy efficacy, safety, and persistence through more predictive and iterative therapy development and rapid, highly-controlled clinical cell manufacturing. For more information, please visit http://www.xcellbio.com/.

Cell and gene therapies, as well as viral vaccines, need higher production yields—and thats where we excel. We significantly increase yields by targeting the innate cellular defenses within production cells. These natural defenses, designed to combat foreign genetic material and inhibit viral replication, can hinder your process. Our solution is a unique panel small molecules which make up our Viral Sensitizer (VSETM) platform, which dampen cellular defenses. Using an innovative high-throughput screening process, we have developed a library of novel VSEs. Virica continues to leverage this advanced technology to pinpoint the most synergistic Viral Sensitizer molecules from our library, tailored to any virus or cell line. We customize formulations of these Viral Sensitizers to enhance virus yield in your manufacturing process or optimize the effectiveness of your viral therapies. The result is higher yields and improved quality, helping to reduce costs and improve patient access.

RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and exosome/extracellular vesicle (EV) product and process development to fuel the rapid implementation of scalable advanced therapies. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and exosome production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type II Drug Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under one year. RoosterBio is driven by our clients success and creating a world where safe and effective advanced therapies are rapidly developed and widely available on a global scale.

FloDesign Sonics was a small start-up biotech in Western Massachusetts, developing acoustic-based cell processing tools, first and foremost the ekko(TM). The company was acquired by MilliporeSigma/Merck KGaA in 2019, and this page is no longer supported.

Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. We focus on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Our breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug-targets and develop RNA therapeutics through partnerships and collaborations with Biopharma. Our in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.

Our mission is to fast-track therapeutics development with improved properties and performance. We are revolutionizing the design of next-generation drug products by leveraging active machine learning, advanced robotics and deep pharmaceutical expertise. Our unique closed-loop technology helps us deliver innovation in every molecule we touch.

Vernal Biosciences is a CDMO democratizing the use of mRNA through a quality-first approach to manufacturing mRNA for all purposes.

Founded in 2018, Seattle-based Alpenglow Biosciences is a privately held, early-stage life sciences company focused on accelerating drug development and improving clinical diagnostics with AI-enabled, 3D imaging technology. Our platform solution provides new spatial biology insights with greater accuracy by digitizing entire tissues while keeping samples intact for additional analysis. Alpenglow partners with pharmaceutical companies to develop better therapeutics and greater understanding of biodistribution, mechanism of action, and rank ordering of potential candidates using our patented technology. Five of the top 10 pharma companies work with Alpenglow to accelerate development timelines, gain new insights, and improve therapeutic success. We are hiring talented individuals for roles in business development, wet lab, hardware, and software.

"Human Data for Next Generation Medicines" Curi Bio unlocks novel workflows and critical human data to inform R&D decision-making. Through an integrated platform featuring advanced 3D tissue models of disease, biosystems enabling clinically relevant functional analyses, and AI/ML-enabled insights, Curi Bio merges functional and analytical assessments for drug safety, efficacy, and potency

CellFE is a cell engineering startup that enables development and manufacturing of the new generation of medicines – cell therapies. CellFE has developed a unique microfluidic platform to solve one of the most pressing issues of therapeutic cell engineering –efficiently delivering gene-editing molecules into cells while preserving cell viability. CellFE’s technology: • Enables development of previously inaccessible cell therapies by providing means for transporting hard-to-deliver molecules into the cells. • Accelerates commercialization of existing cell therapies by significantly reducing cost, complexity, and processing time, while improving the efficacy and safety of the cell engineering process.